| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33130 | |||
| IHC-Prediluted | NBP2-45339 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27416 | |||
| BSA Free | NB100-56712SS | |||
| Azide and BSA Free | NBP2-27416SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56112SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-90592SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64895SS | |||
| Azide and BSA Free | NBP2-80651 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-892SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-648SS | |||
| Azide and BSA Free | NBP2-81006 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2688SS | |||
| Azide and BSA Free | NBP2-80873 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78486SS | |||
| Azide and BSA Free | NBP2-80884 | |||
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Western-Blot-NB600-1160-img0013.jpg "Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)")
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Immunofluorescence Analysis of T98G cells labeling Pgp9.5 with UCH-L1/PGP9.5 Antibody (31A3) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Nucspot (Red)](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunocytochemistry-Immunofluorescence-NB600-1160-img0012.jpg)
![Immunohistochemistry-Paraffin: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Formalin-fixed, paraffin-embedded human brain stained with UchL1 antibody (PGP9.5) (1:500), peroxidase-conjugate and DAB chromogen. Staining seen in cytoplasm, ER and membrane. Fixation in 95% ethanol/5% acetic acid for 2-3 hours prior to paraffin embedding is recommended. Specimens which have not been fixed in acetic acid/alcohol require pre-treatment with citrate buffer: for example, unmask of the target epitope by boiling the tissue sections in 10mM citrate buffer, pH 6.0, for 10 min followed by cooling at room temp for 20 min.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunohistochemistry-Paraffin-NB600-1160-img0004.jpg)
![Flow Cytometry: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Flow Cytometric Analysis of T98G cells using UCH-L1/PGP9.5 Antibody (31A3)followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Flow-Cytometry-NB600-1160-img0011.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of UchL1 in 1) human, 2) mouse and 3) rat brain lysate using UchL1 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Western-Blot-NB600-1160-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of PGP9.5 in rat mesenteric artery using anti-PGP9.5 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunocytochemistry-Immunofluorescence-NB600-1160-img0005.jpg)
![Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Simple Western lane view shows a specific band for PGP9.5 / UCHL-1 in 0.2 mg/ml of h. Cerebellum (left) and IMR-32 (right) lysate(s). This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Simple-Western-NB600-1160-img0006.jpg)
![Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Electropherogram images of the corresponding Simple Western lane. PGP9.5 / UCHL-1 antibody was used at 10 ug/ml dilution of h. Cerebellum and IMR-32 lysates(s) respectively.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Simple-Western-NB600-1160-img0010.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0013.jpg "Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.")
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lane view shows a specific band for NFkB p65 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0006.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lysates of HeLa human cervical epithelial carcinoma cell line and Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 ug/mL mouse anti-RelA/NFkB p65 monoclonal (NB100-56712, Novus Biologicals), followed by 1:2000 dilution of the appropriate HRP-conjugated secondary antibody, donkey anti-mouse IgG (HAF018).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0016.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Ovarian cystadenocarcinoma probed with p65 antibody at 5 ug/mL. Human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Immunohistochemistry-Paraffin-NB100-56712-img0009.jpg)
![Flow Cytometry: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Intracellular staining of 293 HEK cells using 0.5 ug of p65 antibody. Green histogram represents the isotype control (p65) antibody. This NFkB p65 antibody was used for this test with an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Flow-Cytometry-NB100-56712-img0004.jpg)
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Detection of p65 by Simple Western (JESS) in chemiluminescence in nuclear extract of reconstructed human epidermis lysate (about 600 ug/mL protein concentration).Antibody at 1:20. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0017.jpg)
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0008.jpg "Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).")
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - PTD-p65-P1 peptide inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30 min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0009.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26505) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser276-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26505-img0010.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody [NB110-58872] - Analysis of equal amounts of different tissue and cell lysates using chicken pAb to UCHL1, NB110-58872, dilution 1:2,000 in green, and mouse mAb to Actin, dilution 1:1,000, in red: [1] protein standard, [2] rat brain, [3] mouse brain, [4] NIH-3T3, [5] HEK293, [6] HeLa and [7] SH-SY5Y cells. The single band at 24 kDa mark corresponds to UCHL1 protein which is detectable in CNS extracts and lysates of cells with neuronal properties but not in lysates of HeLa, NIH-3T3 and other non-neuronal cells. Actin is detected with apparent molecular weight of 42 kDa and provides an excellent loading control.](http://images.novusbio.com/fullsize/UCH-L1-PGP9.5-Antibody-Western-Blot-NB110-58872-img0002.jpg "Western Blot: UCH-L1/PGP9.5 Antibody [NB110-58872] - Analysis of equal amounts of different tissue and cell lysates using chicken pAb to UCHL1, NB110-58872, dilution 1:2,000 in green, and mouse mAb to Actin, dilution 1:1,000, in red: [1] protein standard, [2] rat brain, [3] mouse brain, [4] NIH-3T3, [5] HEK293, [6] HeLa and [7] SH-SY5Y cells. The single band at 24 kDa mark corresponds to UCHL1 protein which is detectable in CNS extracts and lysates of cells with neuronal properties but not in lysates of HeLa, NIH-3T3 and other non-neuronal cells. Actin is detected with apparent molecular weight of 42 kDa and provides an excellent loading control.")
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - (A) Immunolabeling of the neuronal marker UCHL1 and TRPV1 in frozen DRG sections and cultured sensory neurons from rat. TRPV1 is selectively expressed in a subpopulation of sensory neurons. (B) Representative view field showing the automated image analysis to quantify TRPV1 expression in cultured sensory neurons. Green encircled objects represent sensory neurons marked by UCHL1. Image collected and cropped by CiteAb from the following publication (journals.plos.org/plosone/article?id=10.1371/journal.pone.0115731), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/UCH-L1-PGP9.5-Antibody-Immunocytochemistry-Immunofluorescence-NB110-58872-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Analysis of cortical neuron-glial cell culture from E20 rat stained with chicken pAb to UCHL1, NB110-58872 , dilution 1:500 in red, and costained with mouse mAb to vimentin, dilution 1:2,000, in green. The blue is DAPI staining of nuclear DNA. The UCHL1 antibody produces strong staining of the cell body and dendrites in neurons. The vimentin antibody stains intermediate filaments in fibroblastic and developing glial cells.](http://images.novusbio.com/fullsize/UCH-L1-PGP9.5-Antibody-Immunocytochemistry-Immunofluorescence-NB110-58872-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-310202416212311.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - PGD2 is a paracrine mediator synthesized in myelinated large-diameter neurons acts on TRPV1(+) neurons.(A) Dose-dependent induction of RII phosphorylation in sensory neurons after 1 min stimulation w/ PGD2 (EC50 = 377 nM, n = 3,>2000 neurons/condition; one-way ANOVA w/ Bonferroni's multiple comparisons test). (B) PGD2 did not induce pRII in non-neuronal cells of same cultures shown in A. (C) Time course of RII phosphorylation indicating long-lasting effects of PGD2 (10 µM) on sensory neurons. (D) Stimulation w/ PGD2 also results in phosphorylation of ERK1/2 measured in same cultures shown in D. (E) Representative experiment demonstrating induction of RII phosphorylation is enhanced in TRPV1(+) neurons (total of 3664 neurons). Plots of respective controls are shown in S2 Fig. (F) Fold changes of pRII intensities in TRPV1(−) (grey bars) & TRPV1(+) (black bars) neurons after 1 min stimulation w/ 10 µM PGD2 (n = 3,>2000 neurons/condition, one-way ANOVA w/ Bonferroni's multiple comparisons test). (G) Co-labeling of TRPV1 & PTGDS revealing PTGDS is expressed in neurons lacking TRPV1 (total of 9951 neurons, also refer to S2 Fig. for control plots). (H) Co-labeling of NF200 & PTGDS showing PTGDS(+) neurons express NF200 (total of 12966 neurons, also refer to S2 Fig. for control plots).(I) Size distribution of PTGDS(+) (green), NF200(+) (red), & all sensory neurons (black) indicating PTGDS(+) neurons are larger than other neurons. (J) Suggested pathway of interneuronal communication between subgroups of sensory neurons. Large-diameter mechanosensitive neurons express PTGDS resulting in production of PGD2, which activates DP1 receptors present on nociceptive neurons expressing TRPV1. Image collected & cropped by CiteAb from following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-31020241621833.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-31020241620379.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-310202416235521.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-31020241623555.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-3102024162498.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-310202416235515.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0010.jpg "Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).")
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue 1:300 dilution of rabbit polyclonal Caspase-3 Antibody - (Pro and Active)(NB100-56112), for 1 hour at room temperature followed by anti-rabbit IgG VisUCyte HRP polymer(VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0011.jpg)
![Simple Western: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Simple Western lane view shows a specific band for Caspase 3 in 0.2 mg/ml of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Simple-Western-NB100-56112-img0009.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Effect of acute Cd exposure on BPH1 cell proliferation, Shh signaling activation, and stem cell markers in a time-dependent manner. Cells were incubated with or without 10 uM Cd for the indicated time. Cell lysates were subjected to western blotting using antibodies against p65, Bcl2, BclxL, XIAP, cleaved caspase-3, cleaved PARP, and actin was used as loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-020-0202-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0012.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 expression in formalin-fixed, paraffin-embedded human reactive lymph node using NB100-56112 (Caspase-3 Antibody - (Pro and Active)) at 1:2000. Staining is seen in the apoptosis-prone germinal center B lymphocytes of follicles.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0008.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3 expression in formalin-fixed, paraffin-embedded human breast ductal carcinoma in situ using this antibody at 1:2000. Staining is seen in the the cancerous ducts, but not in the normal lobulus.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB110-90592 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunocytochemistry-Immunofluorescence-NB110-90592-img0008.jpg "Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB110-90592 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB110-89717 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunocytochemistry-Immunofluorescence-NB110-90592-img0009.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody [NB110-90592] - Deregulated MYC transforms breast acini into invasive breast carcinoma in vivo. Tumours harvested in Figure 1C were stained (above) for Ki67/MKI67 and TUNEL and were quantified (below) for the degree of Ki67/MKI67 and TUNEL staining. Individual quantifications per tumour are shown; *P<=0.05, ***P<=0.001, one-way ANOVA with Bonferroni post-test for multiple testing. Scale bar: 100 um. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.038083), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunohistochemistry-NB110-90592-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-Ki-67/MKI67 (NB110-90592) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Chromatin-Immunoprecipitation-NB110-90592-img0003.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody [NB110-90592] - Detection of human lymph node. (20X)](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunohistochemistry-NB110-90592-img0004.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody [NB110-90592] - Detection of human lymph node. (40X)](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunohistochemistry-NB110-90592-img0005.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0005.jpg "Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.")
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using the FITC conjugate of CD45 antibody (OX-1). Staining of rat spleen cells.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0004.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) - BSA Free [NB100-64895] - Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1 (NB110-68095AF488), CD31, and CD45 (NB100-64895PE). LSECs were then identified as SE-1-Alexa488+ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45+ CD31+ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33246411/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-BSA-Free-Flow-Cytometry-NB100-64895-img0006.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Staining of rat peripheral blood lymphocytes with mouse anti-rat CD45 antibody (OX-1) [NB100-64895].](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0001.jpg)
![Western Blot: DLL4 Antibody [NB600-892] - Western Blot of DLL4 antibody. Lane 1: Mouse Pancreas Whole Cell Lysate. Lane 2: HUVEK Whole Cell Lysate.Lane 3: Human rDLL4.Lane 4: HEK293 Whole Cell Lysate + Human rDLL4. Lane 5: HEK293 Whole Cell Lysate.Load: 10 ug per lane for Whole Cell Lysates or 50 ng for recombinant protein.Primary antibody: DLL4 antibody at 1:1,000 overnight at 4C.Secondary antibody: Peroxidase rabbit secondary antibody at 1:40,000 for 30 min at RT.Block: Blocking Buffer for Fluorescent Western Blotting for 30 min at RT.Predicted/Observed size: 74 kDa, 74 kDa for DLL4. Other band(s): Not Identified.](http://images.novusbio.com/fullsize/DLL4-Antibody-Western-Blot-NB600-892-img0006.jpg "Western Blot: DLL4 Antibody [NB600-892] - Western Blot of DLL4 antibody. Lane 1: Mouse Pancreas Whole Cell Lysate. Lane 2: HUVEK Whole Cell Lysate.Lane 3: Human rDLL4.Lane 4: HEK293 Whole Cell Lysate + Human rDLL4. Lane 5: HEK293 Whole Cell Lysate.Load: 10 ug per lane for Whole Cell Lysates or 50 ng for recombinant protein.Primary antibody: DLL4 antibody at 1:1,000 overnight at 4C.Secondary antibody: Peroxidase rabbit secondary antibody at 1:40,000 for 30 min at RT.Block: Blocking Buffer for Fluorescent Western Blotting for 30 min at RT.Predicted/Observed size: 74 kDa, 74 kDa for DLL4. Other band(s): Not Identified.")
![Immunohistochemistry: DLL4 Antibody [NB600-892] - Affinity Purified DLL4 antibody was used at 20 ug/ml to detect DLL4 in a variety of tissues including colon, liver, skeletal muscle, ovary, pancreas, prostate, testes, thymus, tonsil and uterus. In contrast to reported findings, no staining was observed in vascular tissue. This image shows DLL4 staining of human ovary. Tissue was formalin-fixed and paraffin embedded.](http://images.novusbio.com/fullsize/DLL4-Antibody-Immunohistochemistry-NB600-892-img0007.jpg)
![Western Blot: DLL4 Antibody [NB600-892] - Western Blot of DLL4 antibody. Lane 1: mouse pancreatic tissue. Load: 20 ug per lane.Primary antibody: DLL4 antibody at 1:500 for overnight at 4C.Secondary antibody: HRP-labeled Goat anti-Rabbit IgG secondary antibody at 1:5,000 for 1 hour at RT. A chemiluminescence system was used for signal detection using a 3 min exposure time.Block: 5% Goat Serum overnight at 4C.Predicted/Observed size: 74 kDa, 70 kDa for Delta 4. Other band(s): none.](http://images.novusbio.com/fullsize/DLL4-Antibody-Western-Blot-NB600-892-img0005.jpg)
![ELISA: DLL4 Antibody [NB600-892] - ELISA results of purified DLL4 antibody tested against BSA-conjugated peptide of immunizing peptide. Each well was coated in duplicate with 0.1ug of conjugate. The starting dilution of antibody was 5ug/ml and the X-axis represents the Log10 of a 3-fold dilution. This titration is a 4-parameter curve fit where the IC50 is defined as the titer of the antibody. Assay performed using 3% fish gel, Goat anti-Rabbit IgG Antibody Peroxidase Conjugated (Min X Bv Ch Gt GP Ham Hs Hu Ms Rt & Sh Serum Proteins) and TMB ELISA Peroxidase Substrate.](http://images.novusbio.com/fullsize/DLL4-Antibody-ELISA-NB600-892-img0008.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0004.jpg "Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.")
![Western Blot: VEGF Antibody (VG76e) [NB100-648] - Analysis of VEGF in human kidney protein (30ug).](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Western-Blot-NB100-648-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG76e) [NB100-648] - Immunofluorescent analysis of VEGF using NB100-648. This image submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunocytochemistry-Immunofluorescence-NB100-648-img0007.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC-P analysis of VEGF in sheep tonsil using NB100-648. This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0006.jpg)
![Western Blot: Mouse Monoclonal VEGF Antibody (VG76e) [NB100-648] - Bone lysate homogenate from goats. SDS-PAGE with 0.3 mg of total protein from the homogenate per well. VEGF, NB100-648, was used at a dilution of 1:1000 in TBS Tween and 5% milk powder. The protein was labeled at 40 kDa. Quantification of VEGFA in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. Evaluation of pre-cellularized graft in iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to tibial bone defect, G2: cellularized graft for 6 weeks applied to tibial bone defect, G3: cellularized graft for 8 weeks applied to tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 120 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-648_mouse-monoclonal-vegf-antibody-vg76e-western-blot-2952025142053..jpg)
![Western Blot: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and NG2/MCSP (LHM2) knockout (KO) HeLa cell line. PVDF membrane was probed with 1.0 ug/ml of Mouse Anti-Human NG2/MCSP (LHM2) Polyclonal Antibody (Catalog # NB100-2688) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for NG2/MCSP (LHM2) at approximately 300 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Knockout-Validated-NB100-2688-img0015.jpg "<b>Genetic Strategies Validation. </b>Western Blot: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and NG2/MCSP (LHM2) knockout (KO) HeLa cell line. PVDF membrane was probed with 1.0 ug/ml of Mouse Anti-Human NG2/MCSP (LHM2) Polyclonal Antibody (Catalog # NB100-2688) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for NG2/MCSP (LHM2) at approximately 300 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Analysis of NG2 expression in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Western-Blot-NB100-2688-img0006.jpg)
![Immunohistochemistry-Paraffin: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Staining of NG2 in human brain using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Immunohistochemistry-Paraffin-NB100-2688-img0005.jpg)
![Flow Cytometry: NG2/MCSP Antibody (LHM 2) [NB100-2688] - A cell surface stain was performed on SK-MEL-28 cells with NG2/MCSP antibody (LHM 2) NB100-2688AF700 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cytometry-NB100-2688-img0014.jpg)
![Flow Cytometry: NG2/MCSP Antibody (LHM 2) [NB100-2688] - Antibody was tested at 1:400 in MCF7 cells using an Alexa Fluor 488 secondary (shown in green) alongside unstained cells (shown in red).](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cytometry-NB100-2688-img0004.jpg)
![Flow (Cell Surface): NG2/MCSP Antibody (LHM 2) [NB100-2688] - A cell surface stain was performed on U87MG cells with NG2/MCSP antibody (LHM 2) NB100-2688PCP (blue) and a matched isotype control NBP2-27287PCP (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Peridinin-Chlorophyll-Protein complex.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cell-Surface-NB100-2688-img0009.jpg)
![Flow (Cell Surface): NG2/MCSP Antibody (LHM 2) [NB100-2688] - A cell surface stain was performed on U87MG cells with NG2/MCSP antibody (LHM 2) NB100-2688AF647 (blue) and a matched isotype control NBP2-27287AF647 (orange). Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cell-Surface-NB100-2688-img0010.jpg)
![Flow (Cell Surface): NG2/MCSP Antibody (LHM 2) [NB100-2688] - A surface stain was performed on A375 Cells with NG2/MCSP (LHM2) antibody NB100-2688 (blue) and a matched isotype control NBP1-43319 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/NG2-MCSP-Antibody-LHM-2-Flow-Cell-Surface-NB100-2688-img0013.jpg)
![Western Blot: Notch-1 Antibody (mN1A) [NB100-78486] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and Notch-1 knockout (KO) HeLa cell line. PVDF membrane was probed with 2.0 ug/mL of Mouse Anti-Human Notch-1 Monoclonal Antibody (Catalog # NB100-78486) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for Notch-1 at approximately 110 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Knockout-Validated-NB100-78486-img0011.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Notch-1 Antibody (mN1A) [NB100-78486] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and Notch-1 knockout (KO) HeLa cell line. PVDF membrane was probed with 2.0 ug/mL of Mouse Anti-Human Notch-1 Monoclonal Antibody (Catalog # NB100-78486) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for Notch-1 at approximately 110 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: Notch-1 Antibody (mN1A) [NB100-78486] - Cell extracts from Jurkat (Lane 1) or mouse thymocytes (Lane 2) were analyzed with monoclonal anti-NOTCH1 antibody. The mN1A antibody recognizes both mouse and human 270 kDa full-length NOTCH1 and 110-120 kDa cleaved NOTCH 1 (NICD).](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Western-Blot-NB100-78486-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Notch-1 Antibody (mN1A) [NB100-78486] - The Notch1 Antibody was tested in HEK293 cells at a 1:50 dilution with DyLight 488 (Green). Actin was counterstained with Phalloidin 568 (Red) and cells were mounted in DAPI Flouromount (Blue).](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Immunocytochemistry-Immunofluorescence-NB100-78486-img0008.jpg)
![Immunohistochemistry-Paraffin: Notch-1 Antibody (mN1A) [NB100-78486] - Analysis of FFPE human pancreatic cancer using 1:10 dilution of Notch-1 antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) was performed using Aperio AT2 (Leica Biosystems). Cytoplasmic staining in epithelial cells was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Immunohistochemistry-Paraffin-NB100-78486-img0010.jpg)
![Flow Cytometry: Notch-1 Antibody (mN1A) [NB100-78486] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and MCF-7 (B) cells using Notch1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Notch-1-Antibody-mN1A-Flow-Cytometry-NB100-78486-img0007.jpg)
